Mirapex (Pramipexole) for Depression — 2026 ⚠ OE Audit: CAUTION 切換：雲端版 ↗
1

Background & Pharmacology

Pramipexole (brand name Mirapex; generic also available as pramipexole dihydrochloride) is a non-ergot dopamine agonist — the S-(−)-enantiomer of 2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole. It has been FDA-approved for Parkinson's disease (motor symptoms) and restless legs syndrome since 1997 and 2006 respectively. Its use in mood disorders is entirely off-label.[19]

PropertyDetails
Drug classNon-ergot dopamine agonist (S-enantiomer)
Receptor profileD3 ≫ D2 > D4 (dopamine); negligible affinity for D1, serotonin, adrenergic receptors
Half-life8–12 h (immediate release); 24 h (extended release)
Renal excretion~90% unchanged; dose adjustment required for CrCl <30 mL/min
Approved indicationsPD (motor), RLS
Off-label usesMDD, bipolar II depression, TRD augmentation, PD-depression, fibromyalgia
Available formulationsIR (0.125, 0.25, 0.5, 1.0, 1.5 mg) · ER (0.375, 0.75, 1.5, 2.25, 3.0, 3.75, 4.5 mg)

Key foundational RCTs supporting antidepressant use predate 2016 (classic references): Corrigan et al. 2000 (J Clin Psychiatry, first placebo-controlled RCT in MDD); Calabrese et al. 2004 (Am J Psychiatry, landmark bipolar II RCT n=22); Goldberg et al. 2004 (Am J Psychiatry, bipolar I/II augmentation).

~150PubMed / OE / Local
→
~90Deduplicated
→
~40Title/Abstract Screen
→
~25Full-text Assessed
→
19Included in Review

PRISMA-style flow. Local resources: Local Drive ↗ · AW Slide Local Drive ↗ (valid to 2027-05-07) · DA PPT Local Drive ↗

重點整理 Pramipexole (Mirapex) 為非麥角類多巴胺受體促效劑，對 D3 受體親和力最強。台灣核准適應症為巴金森病（運動症狀）與不寧腿症候群。 用於憂鬱症屬於 off-label 使用，需充分告知病人並謹慎監測。
2

Mechanism of Antidepressant Action

Pramipexole's antidepressant properties are mediated through the mesolimbic dopaminergic system, primarily via D3 receptor agonism in the ventral striatum and nucleus accumbens — circuits regulating reward, motivation, and anhedonia.[13]

Reward Learning — Value Preservation Model

Halahakoon & Browning (2024, Biol Psychiatry) conducted a double-blind RCT in 40 healthy volunteers (pramipexole 1 mg/day titrated over 2 weeks vs placebo). fMRI during probabilistic reward learning showed:[14]

  • Increased BOLD response in orbitofrontal cortex (OFC) during reward expectation
  • Decreased BOLD to reward prediction errors in ventromedial PFC (vmPFC)
  • Mechanism: reduced value decay (not increased reward sensitivity or decision temperature)
  • Result: enhanced choice accuracy in reward condition (win trials only; no effect on losses)
Evidence — Mechanism The value-preservation model means pramipexole maintains learned reward expectations — a plausible substrate for reversing the anhedonia and reward-learning deficits characteristic of MDD. This is mechanistically distinct from SSRIs (serotonin-mediated emotional blunting reversal) and ketamine (rapid glutamatergic neuroplasticity).

Response Predictors (Biomarker Approach)

Whitton et al. (2020, Brain, n=26 MDD open-label pramipexole)[15] found — counterintuitively — that patients with stronger baseline reward learning and lower D2/3 receptor availability and dopamine release predicted greater improvement (Cohen's d 0.51–2.16 across symptom subscales). This suggests a "tonic hypo-DA" phenotype (not severe baseline deficit) responds best.

Neurotrophic Effects

Mishra et al. (2025) showed serum BDNF and NGF levels increased significantly after 8 weeks of pramipexole augmentation, although between-group differences vs amantadine/quetiapine were not significant.[7] Additional proposed mechanisms include antioxidant activity and anti-inflammatory effects.[6]

Anhedonia Target Engagement

Ventorp et al. (2026, Nature Medicine) confirmed target engagement via neuroimaging: pramipexole preserved ventral striatal activation during reward processing in anhedonic depression, alongside significant SHAPS improvement (Hedges' g = 0.62).[2]

MechanismEvidenceGRADE
D3 agonism → mesolimbic reward circuitMouse model; neuroimaging RCT⊕⊕⊕⊝ Moderate
Value decay reduction (OFC-vmPFC)fMRI RCT n=40 healthy⊕⊕⊕⊝ Moderate
Ventral striatal target engagementNature Medicine 2026 RCT⊕⊕⊕⊝ Moderate
BDNF/NGF upregulationSingle open-label RCT n=150⊕⊕⊝⊝ Low
Baseline low D2/3 availability predicts responseOpen-label n=26⊕⊕⊝⊝ Low
重點整理 抗憂鬱機轉核心：D3 促效 → 腹側紋狀體活化 → 獎賞學習中「價值保留」增強。 最適合對象：以「失樂感（anhedonia）」為主的憂鬱症患者； 回應預測指標：基線 D2/3 受體佔有率低 + 獎賞學習功能保留較好者回應較佳。 機轉與 SSRI（血清素）、ketamine（麩胺酸）互補，理論上可聯合使用。
3

Pramipexole for Unipolar Major Depressive Disorder

最強證據來源 2025年 Browning 等人發表於 Lancet Psychiatry 的多中心 RCT，是迄今最高品質的 pramipexole 抗憂鬱 單藥增強試驗，效應量 d≈0.87，超過大多數現有 TRD 治療的 meta-analytic estimates。

[1] Browning et al. 2025 — Lancet Psychiatry (LANDMARK RCT)[1]

Multi-centre, double-blind, placebo-controlled RCT. 9 NHS Trusts, England. NIHR-funded. Population: treatment-resistant MDD (≥2 AD failures). n=151 (pramipexole n=75; placebo n=76). Target dose: 2.5 mg/day (mean achieved 2.3 mg at wk 12). Duration: 48 weeks.

OutcomePramipexolePlaceboDifference (95% CI)p
QIDS-SR16 Δ wk 12 (primary)–6.4 (SD 4.9)–2.4 (SD 4.0)–3.91 (–5.37 to –2.45)<0.0001
Standardized effect sized ≈ 0.87 (large)
Secondary outcomes (WSAS, SHAPS, GAD-7, QIDS-C)All significantly superior to placebo
AE discontinuation20%5%—Significant
Main AEsNausea, headache, sleep disturbance / somnolence

Contextual benchmark: pramipexole d=0.87 vs. atypical antipsychotic augmentation d=0.27–0.43 and esketamine d=0.36 in comparable TRD populations. NNH for AE discontinuation ≈ 7.

GRADE: ⊕⊕⊕⊝ Moderate — Rationale Starting High (landmark multicenter double-blind RCT, NIHR-funded); downgrade –1 Imprecision (n=151, relatively small pivotal trial; CI for effect size spans "moderate" to "large"). Future multi-arm trials vs active comparators needed.

[2] Ventorp et al. 2026 — Nature Medicine (Anhedonia-Targeted RCT)[2][18]

Randomized placebo-controlled trial specifically targeting anhedonic depression (Lund, Sweden; protocol pre-registered PMID 38035737). Pramipexole add-on vs placebo, 9 weeks, with 6-month open-label extension.

OutcomeResult
SHAPS Δ (primary)MD –4.04 (95% CI –6.89 to –1.18), p=0.006, Hedges' g=0.62
Neuroimaging target engagementVentral striatal activation preserved; light physical activity increased
Sustained benefitMaintained over 6-month open-label extension

⚠ Not yet indexed in PubMed at time of review (published 2026, DOI confirmed).

GRADE: ⊕⊕⊕⊝ Moderate — Rationale High-impact journal (Nature Medicine); pre-registered RCT; downgrade –1 for inability to fully verify all numbers through PubMed indexing. Target engagement biomarker data strengthens biological plausibility.

[3] Tundo et al. 2019 — Systematic Review & Meta-analysis (Acta Psychiatr Scand)[3]

5 RCTs + 3 open-label + 5 observational studies. n=504. PROSPERO CRD42018108699.

OutcomePramipexoleComparatorEffect (95% CI)
Short-term response rate52.2%——
Short-term remission36.1%——
Long-term remission39.6%~10–11% (traditional AD)Higher long-term
vs Placebo (response, RCTs)—RR 1.77 (1.11–2.82)
vs SSRIs (response, RCTs)—RR 0.93 (0.44–1.95) NS — non-inferior
AE dropout9.6%10.4%NS
GRADE: ⊕⊕⊕⊝ Moderate — Rationale Meta-analysis of RCTs (starting High); downgrade –1 Imprecision (wide CI for vs-SSRI comparison; small per-RCT n; formal non-inferiority not established). Note: vs-SSRI comparison needs dedicated powered trial.
重點整理 — 單極性憂鬱症
  • 效應量突出：Browning 2025 d≈0.87，優於非典型抗精神病藥（d=0.27–0.43）與 esketamine（d=0.36）的 TRD meta-analytic estimates
  • 失樂感靶向：Ventorp 2026 SHAPS 改善 MD –4.04（g=0.62），神經影像確認腹側紋狀體參與
  • 不劣於 SSRI：Tundo 2019 SR/MA RR 0.93，但信賴區間寬，尚待專屬 head-to-head 試驗
  • 副作用：AE 停藥率 20%（Browning 2025），以噁心、頭痛、嗜睡為主
4

Bipolar Depression

Bipolar depression — especially bipolar II — represents one of the most difficult-to-treat mood states, with limited approved pharmacotherapies. Pramipexole emerged as a candidate from early RCTs (Calabrese 2004, Am J Psychiatry, n=22, bipolar II; Goldberg 2004 — classic references) demonstrating superiority over placebo without increased mania switch at short-term follow-up.

[4/5] PAX-BD — McAllister-Williams et al. 2025[4][5]

Multi-centre, double-blind, placebo-controlled RCT. Population: treatment-resistant bipolar depression (TRBD; failure of ≥2 of: quetiapine, olanzapine, lamotrigine, lurasidone). Pramipexole up to 2.5 mg/day added to ongoing mood stabilizer. n=39 (planned n=150; closed early due to COVID-19).

OutcomePramipexole (n=18)Placebo (n=21)Effectp
QIDS-SR Δ wk 12 (primary)–4.4 (SD 4.8)–2.1 (SD 5.1)d=–0.72 (95% CI –0.4 to 6.3)0.087 NS
QIDS-SR Δ wk 36—+6.28 pts (1.85–10.71)Sig
Response at trial exit46%6%—0.026
Remission at trial exit31%0%—0.030
Psychosocial function wk 36—+5.36 pts (0.38–10.35)Sig
Hypomania ratings wk 12Elevated——Sig ↑
安全提醒 — PAX-BD Hypomania ratings were significantly elevated at 12 weeks in the pramipexole arm. Co-prescription of antipsychotics appeared to attenuate this risk. Screen for mixed features and hypomania at every visit when using pramipexole in bipolar patients.
GRADE: ⊕⊕⊝⊝ Low — Rationale Starting High (RCT); downgrade –2 Imprecision (severely underpowered — n=39 vs planned 150; primary endpoint at 12 wk did not reach significance). Longer-term signals (wk 36, trial exit) are statistically significant but must be considered exploratory.

[11] Szmulewicz et al. 2017 — Dopaminergic Agents in Bipolar Depression Meta-analysis (Acta Psychiatr Scand)[11]

OutcomeEffect95% CIN
Response (vs placebo)RR 1.251.05–1.501,671
Remission (vs placebo)RR 1.401.14–1.711,671
Mood switch (vs placebo)RR 0.960.49–1.89 NS1,646
Cumulative switch rate (7.5 mo)3%1.0–5.0%1,231

⚠ Includes mixed DA agents (modafinil, armodafinil, pramipexole, methylphenidate, amphetamines); pramipexole subgroup not separately reported.

GRADE for pramipexole-specific bipolar data: ⊕⊕⊝⊝ Low Indirectness –1 (mixed agent class); Imprecision –1 (pramipexole not separately analyzed). Class-level data supports efficacy and absence of excess switch risk at 7.5 months.

[12] Bahji et al. 2021 — Network Meta-analysis for Adjunctive Bipolar Depression Therapy (Can J Psychiatry)[12]

69 RCTs, n=8,007. Pramipexole among agents significantly more effective than placebo for response (alongside IV ketamine, CoQ10, fluoxetine, lamotrigine). No statistically significant mood switch detected for pramipexole. Fluoxetine had the most consistent efficacy + tolerability evidence base across all agents.

重點整理 — 雙極性憂鬱
  • 短期 primary endpoint 未達顯著（PAX-BD d=–0.72, p=0.087），但因 COVID-19 提早結束，嚴重樣本數不足
  • 長期（36週）及試驗退出點：緩解率 31% vs 0%（p=0.030），有臨床意義的訊號
  • 躁症轉換風險存在：PAX-BD 12週時躁症評分顯著升高；類別層級 meta 分析（7.5月）累積轉換率僅 3%
  • 實務建議：雙極性患者使用時需同時使用心情穩定劑或抗精神病藥，並密切監測情緒轉換
5

Treatment-Resistant Depression (TRD) Augmentation

TRD (failure of ≥2 adequate antidepressant trials) affects ~30% of MDD patients. Pramipexole augmentation targets the dopaminergic gap left by serotonergic/noradrenergic strategies.

[1] Browning 2025 — Lancet Psychiatry (TRD focus)[1]

See Section 3. All 151 participants met TRD criteria. Effect maintained across 48 weeks of follow-up, though placebo patients also improved over time with additional rescue treatments.

[7] Mishra et al. 2025 — Head-to-Head RCT vs Amantadine & Quetiapine (J Affect Disord)[7]

⚠ OE Citation Audit Flag: OpenEvidence incorrectly stated pramipexole dose as "37.5 mg/day." Verified correct dose: 0.375 mg/day (confirmed against PubMed abstract PMID 40659070). This is a 100× decimal transposition error in the OE response. All directional findings remain valid.

Open-label RCT, n=150 TRD (AIIMS Bhubaneswar). Three arms: pramipexole 0.375 mg/day vs amantadine 200 mg/day vs quetiapine 100 mg/day, all added to sertraline. 8 weeks.

MeasurePramipexoleAmantadineQuetiapineBetween-group
HAM-D21 / CGI-S reductionBestModerateModeratePramipexole > both, p<0.001 at wks 4 & 8
BDNF / NGF increaseYesYesYesNS between groups
AE incidencep=0.184 (NS — comparable across arms)

⚠ Open-label, single-centre. Pramipexole dose (0.375 mg) is a starting dose in other trials — likely subtherapeutic relative to Browning 2025 target (2.5 mg). Results should be interpreted with this dose difference in mind.

GRADE: ⊕⊕⊝⊝ Low — Open-label, single centre, detection bias likely

[6] Tundo et al. 2022 — 24-Week Retrospective Cohort (n=116)[6]

Outcome at 24 weeksResult
Response (≥50% HAMD21 reduction)74.1%
Remission (HAMD21 <7)66.4%
GAF score change53 → 80 (p<0.001)
Dropout due to AEs8.6% (n=10)
Hypomanic switch1 patient (0.9%)
ICDs (gambling, hypersexuality, compulsive shopping)0 reported
Median max pramipexole dose1.05 mg/day (IQR 0.72–1.08)
GRADE: ⊕⊝⊝⊝ Very Low — Retrospective, no control group, unblinded, outpatients only

[8] Tundo et al. 2025 — After Aripiprazole Augmentation Failure (n=81)[8]

Patients who previously failed aripiprazole augmentation (n=23, FAA group) vs aripiprazole-naive (n=58, UAA group): no significant difference in response (69.6% vs 77.6%) or remission (60.9% vs 74.1%) at 24 weeks. Suggests pramipexole may rescue patients who have failed standard AA strategies.

GRADE: ⊕⊝⊝⊝ Very Low — Observational, small FAA group
重點整理 — 難治型憂鬱症
  • Browning 2025 為里程碑：第一個規模充足的雙盲 RCT 確認 pramipexole 增強療效（d=0.87）
  • Head-to-head 試驗 vs quetiapine（Mishra 2025）：pramipexole 顯著優於 quetiapine 與 amantadine，但為 open-label 且劑量偏低（0.375 mg）
  • Aripiprazole 失敗後仍有效（Tundo 2025）：觀察性資料顯示 71.6% 回應率
  • 劑量差異：觀察性研究常用 1.05 mg，Browning 2025 目標 2.5 mg——可能反映更高劑量更佳療效但更高 AE 停藥率（20%）
6

PD-Associated Depression

Depression affects 35–50% of PD patients and significantly impairs quality of life. The dopaminergic deficit in PD provides a direct mechanistic rationale for pramipexole's antidepressant use. The critical clinical advantage: simultaneous motor and mood benefit from a single agent.

Local resources: Local Drive ↗ · Local Drive ↗

[9] Wei et al. 2026 — Meta-analysis: Pramipexole vs Antidepressants in PD Depression (J Affect Disord)[9]

12 RCTs, n=772 PD patients with depression. PROSPERO CRD42024525826. Searched 12 databases to Dec 2024.

OutcomeSMD / OR95% CIpGRADE
Depression severity (vs antidepressants)SMD –0.14–0.48 to +0.210.45 NS⊕⊕⊕⊝ Moderate
Tolerability (dropout, any reason)OR 0.780.36–1.710.54 NS⊕⊕⊕⊝ Moderate
Motor symptoms (UPDRS)SMD –0.44–0.82 to –0.050.03 ✓⊕⊕⊕⊝ Moderate
AnorexiaLower with pramipexole—0.05—
Interpretation: Pramipexole = antidepressants for depression severity, but superior for motor symptoms. For PD patients with significant depression AND inadequate motor control, pramipexole is the rational first choice.

[10] Jiang et al. 2021 — Meta-analysis (18 RCTs, n=1,789)[10]

OutcomeEffect95% CIp
Clinical efficacy (RR vs control)RR 1.261.20–1.33<0.00001
HAMD score (SMD vs control)SMD –1.90–2.58 to –1.23<0.00001
Adverse events (RR)RR 0.720.37–1.410.34 NS
⚠ Caution on Jiang 2021 HAMD Effect Size SMD –1.90 is unusually large and almost certainly reflects high heterogeneity and variable quality in included Chinese RCTs (I² not reported in abstract; "control" groups are mixed — levodopa monotherapy, antidepressants, placebo). Wei 2026 (PROSPERO-registered, 12 RCTs, cleaner methodology) is the preferred reference, showing no significant difference vs antidepressants. Do not cite SMD –1.90 as a stand-alone estimate.
GRADE (Jiang 2021): ⊕⊕⊝⊝ Low — High heterogeneity, variable comparator, likely risk of bias

[16] Huang et al. 2025 — Venlafaxine + Pramipexole ± Psychological Care (Actas Esp Psiquiatr)[16]

n=151 PD with depression. Adding structured psychological nursing care to venlafaxine + pramipexole significantly improved HAMD (p<0.0001), HAMA (p<0.0001), and SF-36 (p<0.0001) vs drug therapy alone, without additional AEs. Highlights the value of multimodal treatment.

GRADE: ⊕⊝⊝⊝ Very Low — Retrospective, unblinded, single centre
重點整理 — PD 合併憂鬱
  • 單劑雙效：Wei 2026 MA（12 RCTs, n=772）：憂鬱療效 = 抗憂鬱藥，運動症狀改善 SMD –0.44（p=0.03）優於抗憂鬱藥
  • 選擇策略：PD 患者若憂鬱＋運動症狀控制不足 → 優先考慮 pramipexole（或增加劑量）；若 PD 控制已良好 → SSRI/SNRI 也合適
  • Jiang 2021 SMD –1.90 勿單獨引用：各研究差異大，方法學品質不一
  • 合併心理照護（Huang 2025）：藥物 + 心理護理介入可顯著增強療效
7

Comparative Effectiveness Summary

PopulationComparatorKey EffectSourceGRADE
TRD unipolarPlacebo + ongoing ADQIDS-SR MD –3.91 (–5.37 to –2.45), d≈0.87Browning 2025[1]⊕⊕⊕⊝ Moderate
Anhedonic depressionPlaceboSHAPS MD –4.04 (–6.89 to –1.18), g=0.62Ventorp 2026[2]⊕⊕⊕⊝ Moderate
MDD (pooled)SSRIsRR 0.93 (0.44–1.95) NS — non-inferiorTundo 2019[3]⊕⊕⊝⊝ Low
TRD unipolarQuetiapine 100 mg augmentationPramipexole superior HAM-D (p<0.001)Mishra 2025[7]⊕⊕⊝⊝ Low
TRD unipolarAmantadine 200 mg augmentationPramipexole superior HAM-D (p<0.001)Mishra 2025[7]⊕⊕⊝⊝ Low
TRBD bipolarPlacebo + mood stabilizerRemission 31% vs 0% at exit (p=0.030)PAX-BD 2025[4]⊕⊕⊝⊝ Low
Bipolar depression (class-level)PlaceboResponse RR 1.25 (1.05–1.50); Remission RR 1.40Szmulewicz 2017[11]⊕⊕⊝⊝ Low
PD with depressionAntidepressantsDepression: equivalent (SMD –0.14, p=0.45); Motor: superior (SMD –0.44, p=0.03)Wei 2026[9]⊕⊕⊕⊝ Moderate
TRD after aripiprazole failureAripiprazole-naive TRDResponse 69.6% vs 77.6% (NS)Tundo 2025[8]⊕⊝⊝⊝ Very Low
Contextual Benchmarks Meta-analytic effect sizes for TRD augmentation: atypical antipsychotics d=0.27–0.43 · esketamine d=0.36 · lithium d≈0.30 · pramipexole (Browning 2025) d≈0.87. Head-to-head trials vs these established agents are still needed before pramipexole can be recommended as first-line TRD augmentation.
重點整理 — 比較效益 Pramipexole 在 TRD 及失樂感憂鬱症的效應量（d=0.62–0.87）在現有藥物中突出，但需注意： (1) 目前缺乏 vs esketamine / vs lithium 的 head-to-head 試驗； (2) 在 PD 憂鬱中與傳統抗憂鬱藥療效相當，但運動改善具附加價值； (3) 雙極性憂鬱（PAX-BD）因樣本數不足，尚需確認。
8

Safety & Tolerability

Common Adverse Events

AEPramipexolePlacebo/ComparatorSourceNotes
NauseaMost frequentLowerTundo 2019[3]Dose-dependent; slow titration reduces incidence
HeadacheElevatedLowerBrowning 2025[1]—
Somnolence / sleep disturbanceElevatedLowerBrowning 2025[1]Clinically significant; assess driving safety
AE discontinuation20%5%Browning 2025[1]NNH ≈ 7
Overall dropout9.6%10.4% (SSRIs)Tundo 2019[3]NS vs SSRIs in pooled analysis

Impulse Control Disorders (ICDs)

安全提醒 — ICD 風險 [17] Lindström et al. 2026 (J Affect Disord, Swedish nationwide register cohort):[17] Cumulative pramipexole exposure associated with increased risk of incident gambling disorder in psychiatric patients, with a clear dose-response relationship. Risk was highest in bipolar disorder patients. Absolute risk of clinically diagnosed gambling disorder remains low (reflecting underdiagnosis in registry studies). NNH at antidepressant doses: not established — insufficient powered data.
ICD FindingEvidenceGRADE
ICD at antidepressant doses rarely reported0/116 patients at 24 weeks (Tundo 2022[6])⊕⊝⊝⊝ Very Low
Gambling disorder dose-response in psychiatric patientsSwedish register 2006–2021 (Lindström 2026[17])⊕⊕⊝⊝ Low

Why ICD rates may be underestimated in depression trials: Small sample sizes (n<200), short follow-up (<6 months), outpatient-only selection, and lack of systematic ICD screening tools (e.g., QUIP-RS) in depression RCTs. PD ICD rates are better characterized because pramipexole is standard of care with larger trial populations.

Mood Destabilization / Hypomanic Switch (Bipolar Patients)

SourcePopulationSwitch/Hypomania RateNotes
PAX-BD 2025[4]TRBD (n=39)Significantly elevated at wk 12Attenuated by antipsychotic co-prescription
Tundo 2022[6]Mixed TRD (32% bipolar)1/116 (0.9%) hypomanic switchSmall n; no severe switches
Szmulewicz 2017[11]Bipolar (mixed DA agents)3% cumulative at 7.5 monthsRR 0.96 vs placebo (NS)

Dopamine Agonist Withdrawal Syndrome

Abrupt discontinuation of pramipexole can cause a dopamine agonist withdrawal syndrome (DAWS): anxiety, dysphoria, insomnia, sweating, pain. Taper slowly (reduce by 0.125 mg every 1–2 weeks).

重點整理 — 安全性
  • 噁心最常見：緩慢滴定（每 5–7 天增量）可顯著降低發生率
  • AE 停藥率：Browning 2025 報告 20%（NNH≈7），觀察性研究（低劑量）僅 8–9%
  • ICD 必須監測：雖目前憂鬱症試驗中 ICD 罕見，但瑞典登錄研究已確認劑量反應風險；需每次門診以 QUIP-RS 等工具主動篩查
  • 雙極性患者躁症轉換：必須並用心情穩定劑或抗精神病藥
  • 停藥：勿驟停，應逐步減量以避免戒斷症候群
  • 禁忌：精神病性憂鬱症（多巴胺促效可能誘發精神病）
9

Clinical Application & Dosing

Dosing at Antidepressant Doses

ParameterRecommendationBasis
Starting dose0.125 mg BID or 0.25 mg QDMinimizes nausea, somnolence
TitrationIncrease by 0.125–0.25 mg every 5–7 days as toleratedSlow titration improves tolerability
Target dose (TRD/MDD)1.0–2.5 mg/dayBrowning 2025 target 2.5 mg; Tundo cohorts used median 1.05 mg
PD-depression dose0.5–1.5 mg/day (often combined with levodopa)Wei 2026 meta-analysis
Time to clinical response4–8 weeks (some data suggest 6–12 weeks for full effect)Browning 2025 primary endpoint wk 12
Renal dose adjustmentCrCl 30–59: max 1.5 mg TID; CrCl <30: max 1.5 mg QD or avoidPharmacokinetics

Patient Selection — Optimal Candidate for Pramipexole Augmentation

FeatureFavors PramipexoleCaution / Relative Contraindication
Primary phenotypeAnhedonia-predominant depression (low motivation, no pleasure, reward deficit)Anxious/agitated depression (may worsen)
Prior treatmentFailed ≥2 ADs including SSRI + SNRI or SSRI + atypical APNo prior adequate AD trial (consider standard therapy first)
ComorbiditiesPD with depression; RLS with comorbid depressionPsychotic depression (may precipitate/worsen psychosis)
ICD historyNo prior gambling, hypersexuality, binge eatingPrior ICD or addiction history — use with extreme caution
Bipolar statusBipolar II depression (after mood stabilizer established)Bipolar I, rapid cycling — higher switch risk
Renal functionNormal or mild CKDCrCl <30 — avoid or use minimal dose

Monitoring Protocol

  • Baseline: HAMD/MADRS, QUIP-RS (ICD screen), renal function, PHQ-9, GAF
  • Weeks 2, 4, 8: Symptom response (HAMD or QIDS-SR), QUIP-RS, BP, somnolence
  • Bipolar patients: YMRS or mood diary weekly for first 12 weeks
  • Every visit: Active inquiry for ICD symptoms (gambling, hypersexuality, binge eating, compulsive shopping)
  • Duration: Evidence supports up to 48 weeks (Browning 2025); longer-term data limited
重點整理 — 臨床應用
  • 最佳適應型：以失樂感、動力喪失為核心症狀的難治型憂鬱症（尤其 TRD ≥2 AD 失敗後）
  • 劑量原則：起始 0.125–0.25 mg，緩慢滴定至 1.0–2.5 mg；噁心常見但可改善
  • PD 特別適用：運動+情緒雙重獲益，可合理首選
  • 必須排除：精神病性憂鬱、衝動控制疾患史
  • Taiwan 法規：off-label，需知情同意；建議限神經科/精神科專科開立
10

Research Gaps & Future Directions

GapCurrent StateNeededPriority
Head-to-head vs esketamine/ketamine in TRDNo direct comparison trial existsMulti-arm active comparator RCT🔴 High
Head-to-head vs lithium augmentation in TRDNo direct comparisonActive-comparator RCT🔴 High
Bipolar I vs II subgroup dataPAX-BD did not separate; classic trials too smallAdequately powered bipolar II-specific RCT🔴 High
ICD risk quantification at antidepressant dosesOnly registry data (Lindström 2026); RCTs underpoweredSystematic ICD monitoring in large RCT >500🔴 High
Biomarker-guided patient selectionReward learning / D2/3 PET (Whitton 2020) — small n, open-labelProspective biomarker-stratified RCT🟡 Moderate
Optimal dose for depression (IR vs ER)Browning 2025 used IR 2.5 mg; cohorts used ~1 mgDose-ranging RCT; ER formulation investigation🟡 Moderate
Long-term (>12 months) safety and efficacyBrowning 2025: 48 weeks (longest); observational data beyondExtended follow-up or registry linkage study🟡 Moderate
Combination with ketamine or psychedelicsMechanistic complementarity (DA + NMDA/serotonin)Proof-of-concept trial🟢 Exploratory
PD subpopulation (early vs advanced, with/without dementia)Wei 2026 MA does not subgroup by PD stageStage-stratified analysis or RCT🟡 Moderate
重點整理 — 研究缺口
  • 最急迫的 gap：vs esketamine / vs lithium 的 head-to-head TRD 試驗，以確立 pramipexole 在 TRD 治療序列中的位置
  • 雙極性憂鬱：PAX-BD 樣本數不足，需重複與擴大；PAX-BD 2 或類似研究正在規劃中
  • ICD 風險量化：現有 RCT 均未使用 QUIP-RS 系統性篩查；需主動監測設計
  • 個人化預測：獎賞學習基線 / PET 生物標記在憂鬱症 pramipexole 選案上仍需前瞻性驗證
R

References

  • [1] Browning M, Cowen PJ, Galal U, et al. (PAX-D study group). Pramipexole augmentation for the acute phase of treatment-resistant, unipolar depression: a placebo-controlled, double-blind, randomised trial in the UK. Lancet Psychiatry. 2025;12(8):579–589. PMID 40602411
  • [2] Ventorp F, Asp M, Olsson S, et al. Efficacy and target engagement of dopamine agonist pramipexole for anhedonic depression: a randomized placebo-controlled trial. Nature Medicine. 2026. DOI ↗
  • [3] Tundo A, de Filippis R, De Crescenzo F. Pramipexole in the treatment of unipolar and bipolar depression. A systematic review and meta-analysis. Acta Psychiatr Scand. 2019;140(2):116–125. PMID 31111467
  • [4] McAllister-Williams RH, Goudie N, Azim L, et al. (PAX-BD study group). A randomised double-blind, placebo-controlled trial of pramipexole in addition to mood stabilisers for patients with treatment-resistant bipolar depression (the PAX-BD study). J Psychopharmacol. 2025;39(2):106–120. PMID 39829389
  • [5] McAllister-Williams H, Goudie N, Azim L, et al. Pramipexole in addition to mood stabilisers for treatment-resistant bipolar depression: the PAX-BD randomised double-blind placebo-controlled trial (full HTA report). Health Technol Assess. 2025;29(21):1–216. PMID 40455248
  • [6] Tundo A, Betro' S, Iommi M, de Filippis R. Efficacy and safety of 24-week pramipexole augmentation in patients with treatment resistant depression. A retrospective cohort study. Prog Neuropsychopharmacol Biol Psychiatry. 2022;112:110425. PMID 34375683
  • [7] Mishra BR, Mohapatra D, Biswas T, et al. Comparative efficacy of antidepressant augmentation with amantadine vs pramipexole in treatment-resistant unipolar depression: A randomised controlled trial. J Affect Disord. 2025;390:119891. PMID 40659070
  • [8] Tundo A, Betro' S, de Filippis R, et al. Pramipexole Augmentation for Treatment-Resistant Unipolar Depression Not Responding to Aripiprazole Augmentation: An Observational Study. J Clin Psychopharmacol. 2025;45(3):236–242. PMID 40163774
  • [9] Wei X, Xu F, Zhang X, Browning M, et al. Efficacy and tolerability of pramipexole versus antidepressants for Parkinson's disease with depression: a meta-analysis of randomized controlled trials. J Affect Disord. 2026;392:120087. PMID 40846158
  • [10] Jiang DQ, Jiang LL, Wang Y, Li MX. The role of pramipexole in the treatment of patients with depression and Parkinson's disease: A meta-analysis of randomized controlled trials. Asian J Psychiatr. 2021;61:102691. PMID 33992852
  • [11] Szmulewicz AG, Angriman F, Samamé C, et al. Dopaminergic agents in the treatment of bipolar depression: a systematic review and meta-analysis. Acta Psychiatr Scand. 2017;135(6):527–538. PMID 28256707
  • [12] Bahji A, Ermacora D, Stephenson C, et al. Comparative Efficacy and Tolerability of Adjunctive Pharmacotherapies for Acute Bipolar Depression: A Systematic Review and Network Meta-analysis. Can J Psychiatry. 2021;66(3):274–288. PMID 33174452
  • [13] Halahakoon DC, Browning M. Pramipexole for the Treatment of Depression: Efficacy and Mechanisms. Curr Top Behav Neurosci. 2024;66:49–65. PMID 37982928
  • [14] Halahakoon DC, Kaltenboeck A, Martens M, et al. Pramipexole Enhances Reward Learning by Preserving Value Estimates. Biol Psychiatry. 2024;95(3):286–296. PMID 37330165
  • [15] Whitton AE, Reinen JM, Slifstein M, et al. Baseline reward processing and ventrostriatal dopamine function are associated with pramipexole response in depression. Brain. 2020;143(2):701–710. PMID 32040562
  • [16] Huang Z, Xiao D, Lao Y, et al. The Significance of Psychological Support in Managing Depression in Parkinson's Disease: Combining Venlafaxine with Pramipexole and Psychological Care. Actas Esp Psiquiatr. 2025;53(1):19–25. PMID 39801418
  • [17] Lindström S, Wolfschlag M, Håkansson A, Berge J. Pramipexole exposure and risk of incident gambling disorder in individuals with psychiatric disorders: A nationwide register-based cohort study. J Affect Disord. 2026;412:122033. DOI ↗
  • [18] Lindahl J, Asp M, Ståhl D, et al. Add-on pramipexole for anhedonic depression: study protocol for a randomised controlled trial and open-label follow-up in Lund, Sweden. BMJ Open. 2023;13(11):e076900. PMID 38035737
  • [19] Wilson SM, Wurst MG, Whatley MF, Daniels RN. Classics in Chemical Neuroscience: Pramipexole. ACS Chem Neurosci. 2020;11(17):2506–2512. PMID 32786316